Researchers have determined that children and adults with cancer usually have different mutated genes driving their disease, which suggests they would likely benefit from different therapies.
The finding, from a collaborative study led by St. Jude Children’s Research Hospital, underscores the need to develop precision medicines for paediatric cancer.
The research, along with a companion study led by scientists at the Hopp Children’s Cancer Center at NCT Heidelberg (KiTZ) and the German Cancer Research Center, Heidelberg, appears as an advance online publication in the scientific journal Nature.
The findings from the back-to-back papers provide the most comprehensive analysis yet of the genomic landscape of childhood cancer across multiple subtypes.
The results will help guide clinical and laboratory research to improve understanding, diagnosis and treatment of paediatric cancer patients worldwide, including the estimated 15,780 children and adolescents diagnosed annually in the U.S.
Rather than focusing on a single tumour type, the St. Jude-led study evaluated data generated by members of the Therapeutic Applicable Research to Generate Effective Treatments (TARGET) program.
The scientists evaluated six cancer subtypes using three different, next-generation sequencing approaches.
The researchers compared somatic genetic mutations – genomic changes found in cancer cells but not in normal cells – and their impact on key biological processes in tumour and normal tissues of 1,699 paediatric cancer patients.
The approach, called pan-cancer analysis, revealed that only 45 percent of the mutated genes “driving” cancer in children are the same as the genes “driving” cancer in adults.
“This shows for the first time that paediatric and adult cancers frequently arise from different genes with different mutations,” said corresponding author Jinghui Zhang, Ph.D., chair of the St. Jude Department of Computational Biology.
The first authors are Xiaotu Ma, Ph.D., and Yu Liu, Ph.D., both members of her laboratory.
“The results really bring home the message that paediatric cancer patients are not small adults and their disease should not be treated as if that were the case,” Zhang said.
Treatment advances have pushed cure rates for paediatric cancer to better than 80 percent, but cancer remains the leading cause of death by disease in U.S. children ages 1 to 19.
Treatments often involve major life-long side effects, including the risk of second cancers.
The genomic architecture of paediatric cancers
The analysis included patients enrolled in the clinical trials of the Children’s Oncology Group, a clinical research cooperative.
The patients had acute lymphoblastic leukaemia, both B and T-cell ALL; acute myeloid leukaemia; the bone cancer osteosarcoma; the kidney cancer called Wilms tumour; and neuroblastoma, a tumour of the sympathetic nervous system.
Unlike a previously published adult pan-cancer analysis, which focused primarily on coding sequence mutations, the St. Jude team analysed variations in DNA copies and chromosomal rearrangements.
The data were from whole genome sequencing of the complete DNA of patients’ tumour and normal tissue.
Transcriptome sequencing was also performed.
That provided a snapshot of gene expression in cells.
The analysis also included the first comprehensive evaluation of quantitative and qualitative expression of mutant versus wild-type alleles in multiple cancer subtypes.
The sequencing data was provided by the National Cancer Institute’s TARGET initiative.
TARGET was launched to understand the genetic changes that underlie paediatric cancer.
The intention of the program was to use the data by the research community to improve the precision oncology treatment of paediatric cancers.
For this study, Zhang and her colleagues processed the sequencing data using a uniform analytic framework.
“Looking across tumour types helps to identify really important mutations in paediatric cancer and understand the pathways involved,” she said.
Genomic alterations revealed
For example, the analysis identified unexpected patterns of mutations, or mutational signatures, in eight of the 689 patients with B-ALL.
The patients’ DNA had a mutational signature consistent with exposure to ultraviolet light, which was previously observed exclusively in skin cancers.
The patients also shared another genomic abnormality – too many or too few chromosomes.
In addition, the analysis revealed that rather than point mutations in DNA, a majority (62 percent) of the mutations driving paediatric cancer were copy-number alterations and structural variations.
Copy-number alterations leave patients with too many or too few copies of particular genes.
Structural variations involve gene rearrangements.
“This shows that as genomics moves into the clinic, diagnostic testing for paediatric patients must include copy-number changes and structural variations,” Zhang said.
Data being shared
Zhang and several other St. Jude scientists are also co-authors of a study led by investigators at the German Cancer Research Center.
That study included whole genome and whole exome data from 914 paediatric cancer patients with blood, central nervous system and solid tumours.
The sequencing data came from the St. Jude Children’s Research Hospital–Washington University Paediatric Cancer Genome Project and other sources.
The Paediatric Cancer Genome Project, which began in 2010, sequenced the genomes of more than 800 children and adolescents with some of the least-understood and most difficult-to-treat cancers.
Researchers worldwide can explore somatic mutation data used for both paediatric pan-cancer studies through the St. Jude interactive ProteinPaint portal.
The information, including the genes, mutations and cellular pathways underlying a variety of paediatric cancers, is an unmatched resource for paediatric cancer research going forward.
The TARGET initiative somatic variants used in the analysis are available at the NCI TARTGET Data Matrix, and the sequencing data will be available at the NCI’s Genomic Data Commons.